Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Research & Development (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed Research & Development for 9 consecutive years, with $4.9 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Research & Development fell 33.21% year-over-year to $4.9 million, compared with a TTM value of $30.9 million through Jun 2025, up 78.26%, and an annual FY2025 reading of $19.2 million, down 37.84% over the prior year.
  • Research & Development was $4.9 million for Q2 2025 at VYNE Therapeutics, down from $6.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $10.2 million in Q3 2024 and bottomed at -$180000.0 in Q4 2021.
  • Average Research & Development over 5 years is $5.2 million, with a median of $4.7 million recorded in 2022.
  • The sharpest move saw Research & Development crashed 102.3% in 2021, then skyrocketed 2477.22% in 2022.
  • Year by year, Research & Development stood at -$180000.0 in 2021, then surged by 2477.22% to $4.3 million in 2022, then decreased by 29.35% to $3.0 million in 2023, then skyrocketed by 220.34% to $9.7 million in 2024, then crashed by 49.61% to $4.9 million in 2025.
  • Business Quant data shows Research & Development for VYNE at $4.9 million in Q2 2025, $6.1 million in Q1 2025, and $9.7 million in Q4 2024.